Page 69 - Demo

ANALESRANFwww.analesranf.com16. Caddy SL, Vaysburd M, Papa G, Wing M, O%u2019Connell K,Stoycheva D, et al. Viral nucleoprotein antibodiesactivate TRIM21 and induce T cell immunity. EMBOJ. 2021;40(5):e106228.17. Winkler ES, Bailey AL, Kafai NM, Nair S, McCune BT,Yu J, et al. SARS-CoV-2 infection of human ACE2-transgenic mice causes severe lung inflammationand impaired function. Nat Immunol.2020;21(11):1327-35.18. Toussaint JF, Sailleau C, Breard E, Zientara S, DeClercq K. Bluetongue virus detection by two realtime RT-qPCRs targeting two different genomicsegments. J Virol Methods. 2007;140(1-2):115-23.19. Collier AY, Brown CM, McMahan KA, Yu J, Liu J, JacobDolan C, et al. Characterization of immuneresponses in fully vaccinated individuals afterbreakthrough infection with the SARS-CoV-2 deltavariant. Sci Transl Med. 2022;14(641):eabn6150.20. Zhuang Z, Lai X, Sun J, Chen Z, Zhang Z, Dai J, et al.Correction: Mapping and role of T cell response inSARS-CoV-2-infected mice. J Exp Med.2021;218(11).21. Goel RR, Painter MM, Apostolidis SA, Mathew D, MengW, Rosenfeld AM, et al. mRNA vaccines inducedurable immune memory to SARS-CoV-2 andvariants of concern. Science.2021;374(6572):abm0829.22. Fiolet T, Kherabi Y, MacDonald CJ, Ghosn J, PeifferSmadja N. Comparing COVID-19 vaccines for theircharacteristics, efficacy and effectiveness againstSARS-CoV-2 and variants of concern: a narrativereview. Clin Microbiol Infect. 2022;28(2):202-21.23. Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S,Novak R, et al. Efficacy and Safety of the mRNA1273 SARS-CoV-2 Vaccine. N Engl J Med.2021;384(5):403-16.24. El Sahly HM, Baden LR, Essink B, Doblecki-LewisS, Martin JM, Anderson EJ, et al. Efficacy ofthe mRNA-1273 SARS-CoV-2 Vaccine atCompletion of Blinded Phase. N Engl J Med.2021;385(19):1774-85.25. Frenck RW, Jr., Klein NP, Kitchin N, Gurtman A,Absalon J, Lockhart S, et al. Safety,Immunogenicity, and Efficacy of the BNT162b2Covid-19 Vaccine in Adolescents. N Engl J Med.2021;385(3):239-50.26. Polack FP, Thomas SJ, Kitchin N, Absalon J, GurtmanA, Lockhart S, et al. Safety and Efficacy of theBNT162b2 mRNA Covid-19 Vaccine. N Engl J Med.2020;383(27):2603-15.4. Muik A, Lui BG, Wallisch AK, Bacher M, Muhl J,Reinholz J, et al. Neutralization of SARS-CoV-2Omicron by BNT162b2 mRNA vaccine-elicitedhuman sera. Science. 2022;375(6581):678-80.5. Mannar D, Saville JW, Zhu X, Srivastava SS, BerezukAM, Tuttle KS, et al. SARS-CoV-2 Omicron variant:Antibody evasion and cryo-EM structure of spikeprotein-ACE2 complex. Science.2022;375(6582):760-4.6. Ledford H. %u2018Killer%u2019 immune cells still recognizeOmicron variant. Nature. 2022;601(7893):307.7. Toh ZQ, Anderson J, Mazarakis N, Neeland M, HigginsRA, Rautenbacher K, et al. Comparison ofSeroconversion in Children and Adults With MildCOVID-19. JAMA Netw Open. 2022;5(3):e221313.8. Choi SJ, Kim DU, Noh JY, Kim S, Park SH, Jeong HW,et al. T cell epitopes in SARS-CoV-2 proteins aresubstantially conserved in the Omicron variant.Cell Mol Immunol. 2022;19(3):447-8.9. He X, Aid M, Chandrashekar A, Yu J, McMahan K,Wegmann F, et al. A homologous or variant boostervaccine after Ad26.COV2.S immunizationenhances SARS-CoV-2-specific immune responsesin rhesus macaques. Sci Transl Med.2022;14(638):eabm4996.10. Altmann DM, Boyton RJ. COVID-19 vaccination: Theroad ahead. Science. 2022;375(6585):1127-32.11. Tebas P, Kraynyak KA, Patel A, Maslow JN, Morrow MP,Sylvester AJ, et al. Intradermal SynCon(R) EbolaGP DNA Vaccine Is Temperature Stable and SafelyDemonstrates Cellular and HumoralImmunogenicity Advantages in HealthyVolunteers. J Infect Dis. 2019;220(3):400-10.12. Momin T, Kansagra K, Patel H, Sharma S, Sharma B,Patel J, et al. Safety and Immunogenicity of a DNASARS-CoV-2 vaccine (ZyCoV-D): Results of an openlabel, non-randomized phase I part of phase I/IIclinical study by intradermal route in healthysubjects in India. EClinicalMedicine.2021;38:101020.13. Alcolea PJ, Alonso A, Larraga V. The antibioticresistance-free mammalian expression plasmidvector pPAL for development of third generationvaccines. Plasmid. 2019;101:35-42.14. Scialo F, Daniele A, Amato F, Pastore L, Matera MG,Cazzola M, et al. ACE2: The Major Cell EntryReceptor for SARS-CoV-2. Lung. 2020;198(6):867-77.15. Gussow AB, Auslander N, Faure G, Wolf YI, Zhang F,Koonin EV. Genomic determinants of pathogenicityin SARS-CoV-2 and other human coronaviruses.Proc Natl Acad Sci U S A. 2020;117(26):15193-9.191 an. R. acad. Farm.vol. 91. n%u00ba 2 (2025) %u00b7 pp. 173-192La vacuna no replicativa de ADN, pPAL-S + pPAL-N,libre de genes de resistencia a antibi%u00f3ticos, confiereprotecci%u00f3n completa en ratones frente al SARS-CoV-2Pedro J. Alcolea, Jaime Larraga et al.